Cargando…
Limited HIV-1 Subtype C nef 3′PPT Variation in Combination Antiretroviral Therapy Naïve and Experienced People Living with HIV in Botswana
Dolutegravir (DTG) is a potent anti-HIV drug that is used to treat HIV globally. There have been reports of mutations in the HIV-1 3′-polypurine tract (3′PPT) of the nef gene, contributing to DTG failure; however, there are limited ‘real-world’ data on this. In addition, there is a knowledge gap on...
Autores principales: | Seatla, Kaelo K., Maruapula, Dorcas, Choga, Wonderful T., Morerinyane, Olorato, Lockman, Shahin, Novitsky, Vladimir, Kasvosve, Ishmael, Moyo, Sikhulile, Gaseitsiwe, Simani |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400509/ https://www.ncbi.nlm.nih.gov/pubmed/34451492 http://dx.doi.org/10.3390/pathogens10081027 |
Ejemplares similares
-
HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana †
por: Seatla, Kaelo K., et al.
Publicado: (2021) -
Comparison of an in-house ‘home-brew’ and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples
por: Seatla, Kaelo K., et al.
Publicado: (2019) -
Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use
por: Maruapula, Dorcas, et al.
Publicado: (2023) -
Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana
por: Maseng, Monkgomotsi J, et al.
Publicado: (2021) -
Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naïve HIV-1 Subtype C-infected patients in Botswana
por: Maruapula, Dorcas, et al.
Publicado: (2021)